- Push-out Score determined
- After less than four years in the position
- Thanks for Carmer
- Kristi Jones taking over
(exechange) — Gaithersburg, Maryland, February 17, 2022 — Scott Carmer, chief executive of NexImmune, leaves. As announced by NexImmune Inc. in a news release and in a regulatory filing published on Thursday, February 17, 2022, Scott Carmer has left his post as chief executive officer at the clinical-stage biotechnology company, after less than four years in the role, effective February 12, 2022.
Scott Carmer’s duties as CEO will be taken over by Kristi Jones, most recently Chief Operating Officer at NexImmune Inc.
No reason given
In the announcement, NexImmune did not explicitly explain the reason for the move.
Precise information regarding Scott Carmer’s future plans was not immediately available.
NexImmune said: “Kristi Jones has been appointed as the Company’s Chief Executive Officer and a member of its Board of Directors. Her appointment follows the departure of Scott Carmer, who submitted his letter of resignation this week.”
NexImmune further said: “Scott Carmer had resigned as President and Chief Executive Officer and as a director of the Company effective as of February 12, 2022.”
Share price decline since February 2021
The announcement follows a decline in NexImmune Inc.’s share price of 90% since February 2021.
In the position of CEO since 2018
Scott Carmer became CEO of the Company in 2018.
Scott Carmer has served as the Company’s President and Chief Executive Officer since March 2018 and as a member of the Company’s board of directors since January 2017.
He served as the Company’s Chief Operating Officer from July 2015 to March 2018 and as the Company’s Chief Business Officer from February 2014 to July 2015.
Prior to joining the Company, from 2010 to 2014, Carmer served as Executive Vice President, Commercial Operations of MedImmune, LLC, the former biologics division of AstraZeneca.
From 2006 to 2010, Carmer served as Vice President, Rheumatology Sales & Marketing of Genentech, Inc., or Genentech.
Prior to Genetech, Carmer held several leadership roles of increasing responsibility at Amgen, Inc., most recently as Executive Director of Global Marketing.
Carmer started his career at GlaxoSmithKline plc, where he held key roles in Global Brand Management, Business Development, Commercial Operations, Managed Care and Field Sales.
Carmer earned his B.S. in Biology from the University of Kentucky.
Push-out Score determined
The Push-out Score™ determined by exechange gauges the pressure surrounding Scott Carmer’s move on a scale of 0 to 10.
exechange reached out to NexImmune and offered the company the opportunity to comment on the score.
Read the full story in the exechange report 8.2022 ($).